DK0659082T3 - Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner - Google Patents
Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridinerInfo
- Publication number
- DK0659082T3 DK0659082T3 DK93923110T DK93923110T DK0659082T3 DK 0659082 T3 DK0659082 T3 DK 0659082T3 DK 93923110 T DK93923110 T DK 93923110T DK 93923110 T DK93923110 T DK 93923110T DK 0659082 T3 DK0659082 T3 DK 0659082T3
- Authority
- DK
- Denmark
- Prior art keywords
- cytochrome
- metabolism
- inhibitors
- inhibit
- nitrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Lubricants (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/943,323 US5422350A (en) | 1992-09-10 | 1992-09-10 | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
| US08/100,917 US5466696A (en) | 1992-09-10 | 1993-08-09 | Tacrine and cytochrome P450 oxidase inhibitors and methods of use |
| PCT/US1993/008459 WO1994005296A2 (en) | 1992-09-10 | 1993-09-08 | Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0659082T3 true DK0659082T3 (da) | 2002-06-17 |
Family
ID=26797688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93923110T DK0659082T3 (da) | 1992-09-10 | 1993-09-08 | Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5466696A (da) |
| EP (1) | EP0659082B1 (da) |
| JP (1) | JPH08501105A (da) |
| KR (1) | KR950703339A (da) |
| AT (1) | ATE212845T1 (da) |
| AU (1) | AU669586B2 (da) |
| CA (1) | CA2141425A1 (da) |
| CZ (1) | CZ48095A3 (da) |
| DE (1) | DE69331546T2 (da) |
| DK (1) | DK0659082T3 (da) |
| ES (1) | ES2171419T3 (da) |
| FI (1) | FI951024A (da) |
| HU (1) | HU217845B (da) |
| NO (1) | NO307955B1 (da) |
| NZ (1) | NZ256940A (da) |
| PT (1) | PT659082E (da) |
| SK (1) | SK26495A3 (da) |
| WO (1) | WO1994005296A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| WO2001007069A1 (en) * | 1999-07-22 | 2001-02-01 | Organogenesis Inc. | In vivo induction for enhanced function of isolated hepatocytes |
| JP4355212B2 (ja) * | 2001-12-21 | 2009-10-28 | オーガノジェネシス インコーポレーテッド | 細胞培養及び臓器補助用の可変容量チャンバ |
| US20040092427A1 (en) * | 2002-09-25 | 2004-05-13 | Anil Gulati | Method and composition for treating alzheimer's disease and dementias of vascular origin |
| US7583551B2 (en) | 2004-03-10 | 2009-09-01 | Micron Technology, Inc. | Power management control and controlling memory refresh operations |
| DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
| WO2008153722A1 (en) * | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2233970A (en) * | 1941-03-04 | Quinoline compound and process of | ||
| DE1643240A1 (de) * | 1966-09-16 | 1971-06-24 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane |
| GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
| SU429813A1 (ru) * | 1971-08-20 | 1974-05-30 | Способ лечения туберкулеза легких | |
| AR223983A1 (es) * | 1978-08-25 | 1981-10-15 | Dainippon Pharmaceutical Co | Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico |
| SU789112A1 (ru) * | 1979-04-12 | 1980-12-23 | Научно-исследовательский институт экспериментальной и клинической медицины | Способ лечени экстрасистолической аритмии у детей |
| SU827081A1 (ru) * | 1979-06-05 | 1981-05-07 | Донецкий Медицинский Институт Им.M.Горького | Способ лечени вазомоторных головныхбОлЕй |
| GB2091249A (en) * | 1980-12-23 | 1982-07-28 | Fordonal Sa | Xanthine derivatives |
| SU1049065A1 (ru) * | 1981-01-09 | 1983-10-23 | Andronova Liliya Z | Способ лечени заикани |
| JPS57134482A (en) * | 1981-02-13 | 1982-08-19 | Dainippon Pharmaceut Co Ltd | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation |
| SU1156700A1 (ru) * | 1982-01-19 | 1985-05-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени неврозов |
| SU1210789A1 (ru) * | 1983-07-21 | 1986-02-15 | Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова | Способ диагностики функционального нарушени желудочной секреции |
| SU1196002A1 (ru) * | 1984-06-28 | 1985-12-07 | Запорожский государственный институт усовершенствования врачей им.М.Горького | Способ лечени хронического сальпингоофорита |
| US4631286A (en) * | 1984-10-25 | 1986-12-23 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
| US4695573A (en) * | 1984-10-25 | 1987-09-22 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
| EP0179383B1 (en) * | 1984-10-25 | 1991-05-29 | Hoechst-Roussel Pharmaceuticals Incorporated | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments |
| US4754050A (en) * | 1984-10-25 | 1988-06-28 | Hoechst-Roussel Pharmaceuticals, Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
| US4835275A (en) * | 1984-10-25 | 1989-05-30 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds |
| SU1537252A1 (ru) * | 1985-03-28 | 1990-01-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени парестезий полости рта |
| SU1416125A1 (ru) * | 1986-02-21 | 1988-08-15 | Одесский Научно-Исследовательский Институт Курортологии | Способ лечени заболеваний суставов |
| SU1389050A1 (ru) * | 1986-07-28 | 1990-08-30 | Niiex Meditsiny An Sssr | Cпocoб лeчehия aлkoгoлизma |
| US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| WO1989002739A1 (en) * | 1987-10-05 | 1989-04-06 | Pfizer Inc. | 4-aminopyridine derivatives |
| US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
| KR0156241B1 (ko) * | 1988-11-16 | 1998-11-16 | 도날드 알.토센 | 하이드록시-1,2,3,4-테트라하이드로아미노아크리딘, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| GB8827704D0 (en) * | 1988-11-28 | 1988-12-29 | Fujisawa Pharmaceutical Co | New acridine derivatives & processes for their production |
| US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
-
1993
- 1993-08-09 US US08/100,917 patent/US5466696A/en not_active Expired - Fee Related
- 1993-09-08 EP EP93923110A patent/EP0659082B1/en not_active Expired - Lifetime
- 1993-09-08 CA CA002141425A patent/CA2141425A1/en not_active Abandoned
- 1993-09-08 JP JP6507526A patent/JPH08501105A/ja not_active Ceased
- 1993-09-08 NZ NZ256940A patent/NZ256940A/en unknown
- 1993-09-08 DK DK93923110T patent/DK0659082T3/da active
- 1993-09-08 WO PCT/US1993/008459 patent/WO1994005296A2/en not_active Application Discontinuation
- 1993-09-08 KR KR1019950700943A patent/KR950703339A/ko not_active Application Discontinuation
- 1993-09-08 HU HU9500704A patent/HU217845B/hu not_active IP Right Cessation
- 1993-09-08 SK SK264-95A patent/SK26495A3/sk unknown
- 1993-09-08 CZ CZ95480A patent/CZ48095A3/cs unknown
- 1993-09-08 AT AT93923110T patent/ATE212845T1/de not_active IP Right Cessation
- 1993-09-08 DE DE69331546T patent/DE69331546T2/de not_active Expired - Fee Related
- 1993-09-08 AU AU52905/93A patent/AU669586B2/en not_active Ceased
- 1993-09-08 PT PT93923110T patent/PT659082E/pt unknown
- 1993-09-08 ES ES93923110T patent/ES2171419T3/es not_active Expired - Lifetime
-
1995
- 1995-03-06 FI FI951024A patent/FI951024A/fi unknown
- 1995-03-09 NO NO950909A patent/NO307955B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ48095A3 (en) | 1995-12-13 |
| FI951024A0 (fi) | 1995-03-06 |
| ES2171419T3 (es) | 2002-09-16 |
| NZ256940A (en) | 1996-03-26 |
| EP0659082A1 (en) | 1995-06-28 |
| ATE212845T1 (de) | 2002-02-15 |
| JPH08501105A (ja) | 1996-02-06 |
| WO1994005296A2 (en) | 1994-03-17 |
| CA2141425A1 (en) | 1994-03-17 |
| FI951024A (fi) | 1995-03-06 |
| DE69331546D1 (de) | 2002-03-21 |
| PT659082E (pt) | 2002-07-31 |
| KR950703339A (ko) | 1995-09-20 |
| WO1994005296A3 (en) | 1994-04-28 |
| HUT70979A (en) | 1995-11-28 |
| NO950909D0 (no) | 1995-03-09 |
| NO950909L (no) | 1995-03-09 |
| HU217845B (hu) | 2000-04-28 |
| SK26495A3 (en) | 1996-05-08 |
| AU5290593A (en) | 1994-03-29 |
| US5466696A (en) | 1995-11-14 |
| DE69331546T2 (de) | 2002-10-31 |
| EP0659082B1 (en) | 2002-02-06 |
| NO307955B1 (no) | 2000-06-26 |
| HU9500704D0 (en) | 1995-04-28 |
| AU669586B2 (en) | 1996-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| DE69402173D1 (de) | Hemmung von Thrombin | |
| AU4086101A (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
| TR200000059T2 (tr) | Piridin türevleri | |
| DK0755249T3 (da) | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom | |
| DE69409913D1 (de) | Methode zur Hemmung der Proliferation weiche Muskelzellen und der Restenose | |
| DE69532961D1 (de) | Verwendung von porphyrine in der behandlung von multiple sklerose | |
| DE69326776D1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
| NO952309D0 (no) | Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer | |
| DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
| DK0659082T3 (da) | Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner | |
| NO965094D0 (no) | [aÅ-annelerte pyrrolderivater og anvendelse av disse i farmasien | |
| NO953370L (no) | Anvendelse av riluzol ved behandling av neuro-AIDS | |
| YU32196A (sh) | Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića | |
| NO994330D0 (no) | Metode for behandling av en tumor | |
| UA27910C2 (uk) | Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с | |
| PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro | |
| GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
| DE69218200D1 (de) | Behandlung von leberkrebs | |
| ATE271867T1 (de) | Behandlung der harninkontinenz und zusammenstellung dafür | |
| ATE72115T1 (de) | Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a- | |
| NO960866L (no) | Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler | |
| MD346G2 (ro) | Picoliden-4-izonicotinoilhidrazona dihidrată cu activitate tuberculostatică | |
| IT1263041B (it) | Derivati di s,s'-bis(carbossammidofenil)-disolfuro ad attivita' cardiovascolare |